Navigation Links
Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
Date:2/19/2008

Pamela Harris appointed to lead Diabetes Sales, Managed Care and Government

Accounts on national level

PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 85-year history of innovation and achievement in diabetes care, today announced the company has appointed Pamela Harris as vice president for Diabetes Sales, Managed Care and Government Accounts, effective immediately.

Harris, who since 2005 shared responsibility for managing the diabetes field force, will assume an expanded role of leading the company's 2,000-person field organization of representatives and managed market account executives.

"Pam has developed an impressive and successful track record in sales, managed healthcare, training and marketing," said Jerzy Gruhn, president of Novo Nordisk, Inc. "Her leadership style and strong business experience will help us continue to grow our company and help change the lives of millions of people living with diabetes."

Harris joined Novo Nordisk in 2005 after leading one of the national sales teams at Novartis Pharmaceuticals. In her 28 years in the pharmaceutical industry, she has held various positions in sales leadership roles, training, and marketing. Harris has received several awards recognizing her achievements. At Bristol-Myers Squibb, she was recognized for outstanding leadership and selected from 800 nominees worldwide to receive the Bristol-Myers Squibb Leadership Development Award. Additionally, she has been honored by the Harlem YWCA and was the recipient of their Black Achiever in Industry Award.

Harris received a Bachelor's degree from the College of New Jersey (formerly Trenton State College).

About Novo Nordisk

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
4. Novo Nordisk Increased Net Profit by 32% in 2007
5. Novo Nordisk Files Annual Report with the SEC
6. Adverse housing conditions contribute to diabetes risk
7. RAND finds cases of undiagnosed diabetes drop sharply
8. UCLA researchers identify markers that may predict diabetes in still-healthy people
9. Diabetes appears to increase risk of death for patients with acute coronary syndromes
10. Discovery of sugar sensor in intestine could benefit diabetes
11. Despite overeating, morbidly obese mice gain protection against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: